Google-Backed AI Drug Discovery Startup Isomorphic Labs Pushes Back First Clinical Trials to 2026

Isomorphic Labs, a high-profile artificial intelligence startup focused on drug discovery and backed by Google, has revised its timeline for entering human clinical trials, signaling a delay in its ambitious plans to revolutionize pharmaceutical research.

Founder and Chief Executive Demis Hassabis stated at an event during the World Economic Forum in Davos, Switzerland, on Tuesday that the company now expects to have its first AI-designed drugs in clinical trials by the end of 2026. This marks a shift from his previous assertion last year that the company would achieve this milestone by the end of 2025.

The announcement highlights the challenges and extended timelines inherent in the complex field of drug development, even when powered by cutting-edge AI. Companies across the healthcare and technology sectors have been heavily promoting the potential of AI to accelerate research, reduce costs, and shorten the traditionally decade-long process of bringing new medicines to market. Isomorphic Labs, spun out from Alphabet's AI research arm Google DeepMind in 2021, is one of the most closely watched players in this space.

Hassabis, who also leads Google DeepMind, is renowned for breakthroughs like the AlphaFold AI system, which predicts protein structures—a fundamental task in biology and drug design. Isomorphic Labs aims to build upon this foundation to discover and design novel therapeutic compounds.

The company garnered significant attention and capital last year, raising $600 million in its first external funding round. The round was led by venture capital firm Thrive Capital, underscoring strong investor belief in the convergence of AI and biotechnology, despite the long and uncertain road to commercialization.

The revised timeline from Isomorphic Labs may prompt a more measured evaluation of the near-term impact of AI on drug discovery pipelines. While the technology holds immense promise for identifying drug candidates faster than traditional methods, the subsequent stages of preclinical testing, regulatory approval, and clinical trials remain lengthy and fraught with risk. This delay serves as a reminder to investors and industry observers that while AI can be a powerful tool, it does not eliminate the biological and regulatory complexities of developing safe and effective human medicines.

For parent company Alphabet (GOOGL), Isomorphic Labs represents a strategic bet on applying its core AI expertise beyond digital advertising and into the high-stakes, high-reward life sciences sector. The performance and progress of its portfolio companies in this area are watched as indicators of Alphabet's ability to diversify its revenue streams and create value from its massive research investments. The one-year postponement is unlikely to alter the long-term strategic importance of the venture but may temper some of the more immediate expectations surrounding AI's disruption of pharma.